Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

High nitrate concentrations in drinking water are a potential hazard to human health

A new study exploring the growing worldwide problem of nitrogen pollution from soils to the sea shows that global ratios of nitrogen and carbon in the environment are inexorably linked, a finding that may lead to new strategies to help mitigate regional problems ranging from contaminated waterways to human health.

26 Apr 2010

AFFiRiS' AD02 Alzheimer's vaccine candidate in phase II clinical testing

AFFiRiS AG's clinical Alzheimer's vaccine candidate AD02 has already progressed to phase II clinical testing. It may therefore be possible to confirm the efficacy of the vaccine as early as during 2012. Indeed the start of this efficacy study comes only five months after the completion of the corresponding phase I study. The company is active in several disease areas and is currently developing a total of twelve prospective products in all stages of the development pipeline up to clinical phase II.

24 Apr 2010

Research into Planarian worm 'Smed-prep' gene may pave way for regeneration of human organs

Scientists at The University of Nottingham have discovered the gene that enables an extraordinary worm to regenerate its own body parts after amputation — including a whole head and brain.

23 Apr 2010

Alzheimer's Association's hosts conference to educate and support NH people with the disease

Alzheimer's disease can be devastating to families who become caregivers. Anyone seeking more information about Alzheimer's is invited to attend the Alzheimer's Association's "Care to Cure: the latest in research and care giving" conference on Saturday, May 22 in Concord.

23 Apr 2010

Study describes relationship between gene expression and intelligence in WS patients

Although genetics is the most significant known determinant of human intelligence, how specific genes affect intelligence remains largely unknown. A multi-institution team led by a University of Utah USTAR researcher has found that the brain gene STX1A plays a significant role in the level of intelligence displayed by patients with Williams Syndrome.

23 Apr 2010

COSMOS project launched to investigate link between use of mobile phones and health problems

A new decades-long study launches today to investigate whether there is a link between the use of mobile phones and long-term health problems such as cancer.

23 Apr 2010

Physical exercise and computer use may help protect against mild cognitive impairment: Mayo Clinic

A new Mayo Clinic study found that physical exercise and computer use may help protect against mild cognitive impairment, a disorder of the brain that affects nerve cells involved in thinking abilities.

23 Apr 2010

Baxter International's global sales for first-quarter advances by 11% to $3.1 billion

Baxter International Inc. today reported first quarter net income of $525 million, an increase of 2 percent from $516 million reported in the first quarter of 2009. Earnings per diluted share of $0.86 increased 4 percent from $0.83 per diluted share reported in the prior-year period. Baxter's first quarter financial results included a one-time, non-cash special charge of $39 million (or $0.07 per diluted share) related to a change in the tax treatment of post-retirement prescription drug benefits under recent U.S. healthcare reform legislation.

From Baxter International Inc. 22 Apr 2010

Mild Cognitive Impairment Symposium is now 'Symposium on Early Alzheimer's Disease'

This year, the Miami Beach symposium kicked off on a rainy Friday with a new name and a new focus on biomarkers. For seven years, the meeting has been called the Mild Cognitive Impairment Symposium, but that changed this year to the Symposium on Early Alzheimer's Disease. The change comes as a nod to a recent and dramatic shift in how Alzheimer disease is perceived, and what researchers increasingly see as the most promising angle of attack for future therapeutics.

22 Apr 2010

Larger sized intravenous anesthetic diazepam incubated in isolation with Aβ peptide does not promote aggregation

Alzheimer's disease (AD) is a neurodegenerative disorder affecting millions of people worldwide and has become a major global concern. Uncontrolled oligomerization (aggregation) of Aβ peptide is the hallmark of AD and it is believed to be causally related to AD pathomechanism.

22 Apr 2010

Abbott's first-quarter worldwide pharmaceutical sales increases by 12.9%

Abbott today announced financial results for the first quarter ended March 31, 2010.

21 Apr 2010

CSTE receives $1M gift from NFL to research long-term effects of repetitive brain trauma in football players

The National Football League (NFL) will give a $1 million unrestricted gift to the Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine to support the Center's research.

21 Apr 2010

Elan's first-quarter total revenue up by 27% to $310.5M

Elan Corporation, plc, today reported its first quarter 2010 financial results.

21 Apr 2010

Duke University Medical Center, LabCorp form joint venture to commercialize new biomarkers

Duke University Medical Center and Laboratory Corporation of America Holdings announced today the formation of a joint venture to commercialize new biomarkers. The new entity is designed to speed the translation of newly discovered biomarkers into widely available clinical tools that can measure individual therapeutic responses, predict disease progression, and evaluate any number of biologic or disease-causing processes.

21 Apr 2010

Forest Laboratories' fourth-quarter net sales up 11.0% to $995.6M

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $0.07 in the fourth quarter of fiscal 2010.

21 Apr 2010

Obesity related FTO gene linked to Alzheimer’s disease.

If you are an American of European origin and carry the FTO gene which causes obesity, you have a much higher risk of developing Alzheimer’s disease. A recent study conducted at the University of California, Los Angeles claimed that 'A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in healthy elderly'.

21 Apr 2010

Researchers identify potential drug target for treatment of Alzheimer's disease

Researchers at the University of Illinois have identified a potential drug target for the treatment of Alzheimer's disease: a receptor that is embedded in the membrane of neurons and other cells.

21 Apr 2010

On-going phase II trial of octagam in AD to be discussed at ICAD 2010

The on-going phase II trial on Octapharma's 10% intravenous immunoglobulin octagam®10% will be a topic at the up-coming International Conference on Alzheimer's Disease to take place in Honolulu, Hawaii from July 10 to 15.

20 Apr 2010

FTO gene associated with loss of brain tissue: UCLA researchers

Three years ago, geneticists reported the startling discovery that nearly half of all people in the U.S. with European ancestry carry a variant of the fat mass and obesity associated gene, which causes them to gain weight - from three to seven pounds, on average - but worse, puts them at risk for obesity.

20 Apr 2010

Potential drug to annul ADAM-17 protein activity needed

Over the past four years, in the installations of the Faculty of Medicine, University of Cadiz, a group of researchers, headed by Doctor Carmen Estrada, has been studying neurogenesis - the process of forming new neurons from mother cells - in the adult mammal brain. The purpose of this research project is to contribute to the knowledge of this process with the object of finding some additional mechanism that would facilitate the treatment of pathologies of the central nervous system (CNS) that are suffered in consequence of neuronal death.

19 Apr 2010

Alzheimer's Disease News and Research

Further Reading

High nitrate concentrations in drinking water are a potential hazard to human health

AFFiRiS' AD02 Alzheimer's vaccine candidate in phase II clinical testing

Research into Planarian worm 'Smed-prep' gene may pave way for regeneration of human organs

Alzheimer's Association's hosts conference to educate and support NH people with the disease

Study describes relationship between gene expression and intelligence in WS patients

COSMOS project launched to investigate link between use of mobile phones and health problems

Physical exercise and computer use may help protect against mild cognitive impairment: Mayo Clinic

Baxter International's global sales for first-quarter advances by 11% to $3.1 billion

Mild Cognitive Impairment Symposium is now 'Symposium on Early Alzheimer's Disease'

Larger sized intravenous anesthetic diazepam incubated in isolation with Aβ peptide does not promote aggregation

Abbott's first-quarter worldwide pharmaceutical sales increases by 12.9%

CSTE receives $1M gift from NFL to research long-term effects of repetitive brain trauma in football players

Elan's first-quarter total revenue up by 27% to $310.5M

Duke University Medical Center, LabCorp form joint venture to commercialize new biomarkers

Forest Laboratories' fourth-quarter net sales up 11.0% to $995.6M

Obesity related FTO gene linked to Alzheimer’s disease.

Researchers identify potential drug target for treatment of Alzheimer's disease

On-going phase II trial of octagam in AD to be discussed at ICAD 2010

FTO gene associated with loss of brain tissue: UCLA researchers

Potential drug to annul ADAM-17 protein activity needed

Aneuro: A Year of Neuroscience in Review eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News